Patent application number | Description | Published |
20080249245 | BLENDS OF AMORPHOUS AND SEMICRYSTALLINE POLYMERS HAVING SHAPE MEMORY PROPERTIES - A shape memory polymeric material has a glass transition temperature, T | 10-09-2008 |
20090253842 | SHAPE MEMORY POLYMERS BASED ON SEMICRYSTALLINE THERMOPLASTIC POLYURETHANES BEARING NANOSTRUCTURED HARD SEGMENTS - Thermoplastic polyurethanes having an alternating sequence of hard and soft segments in which a nanostructured polyhedral oligosilsesquioxane diol is used as a chain extender to form a crystalline hard segment constituting SMPs. The polyurethanes are formed by reacting a polyol, a chain extender dihydroxyl-terminated polyhedral oligosilsesquioxane and a diisocyanate. The polyurethanes have multiple applications including for example, implants for human health care, drug delivery matrices, superabsorbant hydrogels, coatings, adhesives, temperature and moisture sensors, etc. | 10-08-2009 |
20090275704 | CROSSLINKED POLYCYCLOOCTENE - Chemically crosslinked polycyclooctene having excellent shape recovery properties is prepared by ring-opening metathesis polymerization of cis-cyclooctene followed by chemical crosslinking. The crosslinked polycyclooctene can be shaped, the shape memorized, a new shape imparted with the original shape being recoverable by suitable temperature adjustment. The dependence of shape memory characteristics on degree of crosslinking was established. In addition to polycyclooctene, blends thereof with other materials such as SBR, EVA, polyurethane rubbers, and inorganic fillers can be utilized to provide chemically crosslinked products having excellent and tailored shape memory properties. | 11-05-2009 |
20100160522 | CROSSLINKED POLYCYCLOOCTENE - Chemically crosslinked polycyclooctene having excellent shape recovery properties is prepared by ring-opening metathesis polymerization of cis-cyclooctene followed by chemical crosslinking. The crosslinked polycyclooctene can be shaped, the shape memorized, a new shape imparted with the original shape being recoverable by suitable temperature adjustment. The dependence of shape memory characteristics on degree of crosslinking was established. In addition to polycyclooctene, blends thereof with other materials such as SBR, EVA, polyurethane rubbers, and inorganic fillers can be utilized to provide chemically crosslinked products having excellent and tailored shape memory properties. | 06-24-2010 |
20100331954 | IMPLANTABLE MEDICAL DEVICES - A medical device includes a balloon catheter having an expandable member, e.g., an inflatable balloon, at its distal end and a stent or other endoprosthesis. The stent is, for example, an apertured tubular member formed of a polymer and is assembled about the balloon. The stent has an initial diameter for delivery into the body and can be expanded to a larger diameter by inflating the balloon. | 12-30-2010 |
20110054591 | IMPLANTABLE MEDICAL DEVICES - A medical device includes a balloon catheter having an expandable member, e.g., an inflatable balloon, at its distal end and a stent or other endoprosthesis. The stent is, for example, an apertured tubular member formed of a polymer and is assembled about the balloon. The stent has an initial diameter for delivery into the body and can be expanded to a larger diameter by inflating the balloon. | 03-03-2011 |
20110071562 | MEDICAL DEVICES - A medical device, such as, for example, a catheter, includes a tubular member having a first portion having a shape memory polymer. | 03-24-2011 |
20110172753 | ENDOPROSTHESES - Endoprosthesis are disclosed. | 07-14-2011 |
20120253451 | IMPLANTABLE MEDICAL DEVICES - A medical device includes a balloon catheter having an expandable member, e.g., an inflatable balloon, at its distal end and a stent or other endoprosthesis. The stent is, for example, an apertured tubular member formed of a polymer and is assembled about the balloon. The stent has an initial diameter for delivery into the body and can be expanded to a larger diameter by inflating the balloon. | 10-04-2012 |
20140067039 | IMPLANTABLE MEDICAL DEVICES - A medical device includes a balloon catheter having an expandable member, e.g., an inflatable balloon, at its distal end and a stent or other endoprosthesis. The stent is, for example, an apertured tubular member formed of a polymer and is assembled about the balloon. The stent has an initial diameter for delivery into the body and can be expanded to a larger diameter by inflating the balloon. | 03-06-2014 |
20140135889 | IMPLANTABLE MEDICAL DEVICES - A medical device includes a balloon catheter having an expandable member, e.g., an inflatable balloon, at its distal end and a stent or other endoprosthesis. The stent is, for example, an apertured tubular member formed of a polymer and is assembled about the balloon. The stent has an initial diameter for delivery into the body and can be expanded to a larger diameter by inflating the balloon. | 05-15-2014 |
Patent application number | Description | Published |
20100298232 | Peptides targeting TNF family receptors and antagonizing TNF action, compositions, methods and uses thereof - The present invention provides modulators of TNF, particularly peptides and their derivatives, particularly GEP peptides, which antagonize TNF and TNF-mediated responses, activity or signaling. The invention provides methods of antagonizing TNF and the modulation of TNF-mediated diseases or responses, including inflammatory diseases and conditions. Compositions of GEP peptides, including in combination with other inflammatory mediators, are provided. Methods of treatment, alleviation, or prevention of TNF-mediated diseases and inflammatory conditions, including rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriasis, inflammatory bowel diseases, Chrohn's disease, ulcerative colitis, uveitis, inflammatory lung diseases, chronic obstructive pulmonary disease, are provided. | 11-25-2010 |
20120230942 | GEP, a novel chondrogenic growth factor and target in cartilage disorders - The present invention relates to the expression and regulating growth factors in chrondrocytes and developing cartilage, particularly granulin-epithelin precursor (GEP). The invention relates to the modulation and manipulation of these growth factors, GEP, and/or the molecules they interact with, for instance COMP, in cartilage disorders, including arthritis. Assays and screening methods for the determination of the expression and activity of GEP, or of GEP-COMP, are provided, including for screening for the presence or extent of cartilage or arthritic disease and for identifying modulators or compounds/agents for treatment or prevention of cartilage or arthritic diseases. | 09-13-2012 |
20130157945 | PEPTIDES TARGETING TNF FAMILY RECEPTORS AND ANTAGONIZING TNF ACTION, COMPOSITIONS, METHODS AND USES THEREOF - The present invention provides modulators of TNF, particularly peptides and their derivatives, particularly GEP peptides, which antagonize TNF and TNF-mediated responses, activity or signaling. The invention provides methods of antagonizing TNF and the modulation of TNF-mediated diseases or responses, including inflammatory diseases and conditions. Compositions of GEP peptides, including in combination with other inflammatory mediators, are provided. Methods of treatment, alleviation, or prevention of TNF-mediated diseases and inflammatory conditions, including rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriasis, inflammatory bowel diseases, Chrohn's disease, ulcerative colitis, uveitis, inflammatory lung diseases, chronic obstructive pulmonary disease, are provided. | 06-20-2013 |
Patent application number | Description | Published |
20100210500 | Personal Wash Compositions Comprising Specific Blends of Saturated (Hydrogenated) Oil to Unsaturated Triglyceride Oils - The present invention provides personal wash compositions where blends of triglyceride oils are specifically formulated to provide functional benefits. Specifically when formulated to have specific blend of saturated to unsaturated oils, perfect balance between, on the one hand, spreadability and deposition and, on the other hand, retention of excellent framing, is achieved. | 08-19-2010 |
20120094884 | Stable Liquid Cleansing Compositions Comprising Critical Window of Hydrogenated Triglyceride Oils - The present invention provides personal wash compositions where hydrogenated triglyceride oils (defined by IV of 0 to <20) are specifically formulated to provide low temperature stability. Specifically when formulated to have specific concentration of hydrogenated triglycerides, delivered as pure sample or from mixtures of hydrogenated and other triglyceride oils, desirable low temperature stability of formulations is achieved. | 04-19-2012 |
20120094885 | Stable Liquid Cleansing Compositions Comprising Critical Window of Partially Hydrogenated Triglyceride Oil of Defined Iodine Value - The present invention provides personal wash compositions where partially hydrogenated triglyceride oil (defined by IV of 20 to 100) are specifically formulated to provide low temperature stability. Specifically when formulated to have specific concentration of partially hydrogenated triglycerides, delivered alone or as part of mixture with other oils, desirable low temperature stability of formulations is achieved. | 04-19-2012 |
20150374592 | PERSONAL CARE COMPOSITIONS THAT INCLUDE ENROBED SUGAR - A personal care composition that comprises: a) a sugar infused with at least one additive, in particular, hair and/or skin benefit agent, wherein the infused sugar is coated with a hydrocarbon layer of selected viscosity and melting point; b) at least 10 wt % water, based on the total weight of the composition, wherein the infused and coated sugar is suspended in the composition as a disperse particle phase. | 12-31-2015 |
Patent application number | Description | Published |
20090325988 | Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof - Compounds of Formula (I) | 12-31-2009 |
20100093724 | Azaindazole Compounds As CCR1 Receptor Antagonists - Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. | 04-15-2010 |
20110086846 | Azaindazole Compounds As CCR1 Receptor Antagonists - Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. | 04-14-2011 |
20110230521 | Pyrazole Compounds As CCR1 Antagonists - Disclosed are compounds of the formula (I) which block the interaction of CCR1 and its ligands and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes. | 09-22-2011 |
20120035370 | Azaindazole Compounds As CCR1 Receptor Antagonists - Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. | 02-09-2012 |
20120136158 | Pyridinyl Compounds Useful As Intermediates - Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. | 05-31-2012 |
20120322790 | Pyrazolopiperidine Compounds As CCR1 Receptor Antagonists - Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. | 12-20-2012 |
Patent application number | Description | Published |
20100166892 | HERBAL COMPOSITION PHY906 AND ITS USE IN CHEMOTHERAPY - This invention provides herbal compositions useful for increasing the therapeutic index of chemotherapeutic compounds. This invention also provides methods useful for improving the quality of life of an individual undergoing chemotherapy. Furthermore, this invention improves the treatment of disease by increasing the therapeutic index of chemotherapy drugs by administering the herbal composition PHY906 to a mammal undergoing such chemotherapy. | 07-01-2010 |
20100255129 | HERBAL COMPOSITION PHY906 AND ITS USE IN CHEMOTHERAPY - This invention provides herbal compositions useful for increasing the therapeutic index of chemotherapeutic compounds. This invention also provides methods useful for improving the quality of life of an individual undergoing chemotherapy. Furthermore, this invention improves the treatment of disease by increasing the therapeutic index of chemotherapy drugs by administering the herbal composition PHY906 to a mammal undergoing such chemotherapy. | 10-07-2010 |
20110111070 | USE OF PHY906 AS TREATMENT FOR INFLAMMATORY BOWEL DISEASE AND/OR IRRITABLE BOWEL SYNDROME - The present invention includes a method of using PHY906 for treating a bowel disorder including inflammatory bowel disease and irritable bowel syndrome. Particularly, the present invention provides a multiple symptoms treatment for the bowel disorder. | 05-12-2011 |
20120009282 | USE OF THE COMBINATION OF PHY906 AND A TYROSINE KINASE INHIBITOR AS A CANCER TREATMENT REGIMEN - This invention provides herbal compositions useful for increasing the therapeutic index of chemotherapeutic compounds. This invention also provides methods useful for improving the quality of life of an individual undergoing chemotherapy. Furthermore, this invention improves the treatment of cancer by administering the herbal composition PHY906 in combination with one or more chemotherapeutic compounds to a mammal undergoing such chemotherapy. | 01-12-2012 |
20130101688 | HERBAL COMPOSITION PHY906 AND ITS USE IN CHEMOTHERAPY - This invention provides herbal compositions useful for increasing the therapeutic index of chemotherapeutic compounds. This invention also provides methods useful for improving the quality of life of an individual undergoing chemotherapy. Furthermore, this invention improves the treatment of disease by increasing the therapeutic index of chemotherapy drugs by administering the herbal composition PHY906 to a mammal undergoing such chemotherapy. | 04-25-2013 |
20150110906 | HERBAL COMPOSITION PHY906 AND ITS USE IN CHEMOTHERAPY - This invention provides herbal compositions useful for increasing the therapeutic index of chemotherapeutic compounds. This invention also provides methods useful for improving the quality of life of an individual undergoing chemotherapy. Furthermore, this invention improves the treatment of disease by increasing the therapeutic index of chemotherapy drugs by administering the herbal composition PHY906 to a mammal undergoing such chemotherapy. | 04-23-2015 |
20150182575 | USE OF PHY906 AS TREATMENT FOR INFLAMMATORY BOWEL DISEASE AND/OR IRRITABLE BOWEL SYNDROME - The present invention includes a method of using PHY906 for treating a bowel disorder including inflammatory bowel disease and irritable bowel syndrome. Particularly, the present invention provides a multiple symptoms treatment for the bowel disorder. | 07-02-2015 |
Patent application number | Description | Published |
20080312185 | SUBSTITUTED 3-AMINO-THIENO[2,3-b]PYRIDINE-2-CARBOXYLIC ACID AMIDE COMPOUNDS AND PROCESSES FOR PREPARING AND THEIR USES - Disclosed are methods of treating cancer by administration of compounds according to formula (I): | 12-18-2008 |
20110224188 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-alpha]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES - Derivatives of 6,7-dihydro-5H-imidazo[1,2-α]imidazole-3-carboxylic acid amide exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease. | 09-15-2011 |
20140357652 | RHO KINASE INHIBITORS - Disclosed are novel substituted 2H-isoquinolin-1-one and 3H-quinazolin-4-one derivatives useful as inhibitors of Rho kinase and for treating a variety of diseases and disorders that are mediated or sustained through the activity of Rho kinase, including cardiovascular diseases, pharmaceutical compositions comprising such compounds, methods for using such compounds and processes for making such compounds. | 12-04-2014 |
20150297581 | RHO KINASE INHIBITORS - Disclosed are novel substituted 2H-isoquinolin-1-one and 3H-quinazolin-4-one derivatives useful as inhibitors of Rho kinase and for treating a variety of diseases and disorders that are mediated or sustained through the activity of Rho kinase, including cardiovascular diseases, pharmaceutical compositions comprising such compounds, methods for using such compounds and processes for making such compounds. | 10-22-2015 |
Patent application number | Description | Published |
20100125139 | PROCESS FOR PREPARING QUINAZOLINE RHO-KINASE INHIBITORS AND INTERMEDIATES THEREOF - A process for the preparation of various quinazoline compounds which are useful as Rho-Kinase inhibitors, and thus having utility in the treatment of hypertension and other indications. | 05-20-2010 |
20100137324 | RHO-KINASE INHIBITORS - Disclosed are compounds and derivatives thereof, their synthesis, and their use as Rho-kinase inhibitors. These compounds of the present invention are useful for inhibiting tumor growth, treating erectile dysfunction, and treating other indications mediated by Rho-kinase, e.g., coronary heart disease. | 06-03-2010 |
20100216789 | RHO-KINASE INHIBITORS - Disclosed are compounds and derivatives thereof, their synthesis, and their use as Rho-kinase inhibitors. These compounds of the present invention are useful for inhibiting tumor growth, treating erectile dysfunction, and treating other indications mediated by Rho-kinase, e.g., coronary heart disease. | 08-26-2010 |
Patent application number | Description | Published |
20110247005 | Methods and Apparatus for Resource Capacity Evaluation in a System of Virtual Containers - Methods and apparatus are provided for evaluating potential resource capacity in a system where there is elasticity and competition between a plurality of containers. A dynamic potential capacity is determined for at least one container in a plurality of containers competing for a total capacity of a larger container. A current utilization by each of the plurality of competing containers is obtained, and an equilibrium capacity is determined for each of the competing containers. The equilibrium capacity indicates a capacity that the corresponding container is entitled to. The dynamic potential capacity is determined based on the total capacity, a comparison of one or more of the current utilizations to one or more of the corresponding equilibrium capacities and a relative resource weight of each of the plurality of competing containers. The dynamic potential capacity is optionally recalculated when the set of plurality of containers is changed or after the assignment of each work element. | 10-06-2011 |
20120060171 | Scheduling a Parallel Job in a System of Virtual Containers - Methods and apparatus are provided for scheduling parallel jobs in a system of virtual containers. At least one parallel job is assigned to a plurality of containers competing for a total capacity of a larger container, wherein the at least one parallel job comprises a plurality of tasks. The assignment method comprises determining a current utilization and a potential free capacity for each of the plurality of competing containers; and assigning the tasks to one of the plurality of containers based on the potential free capacities and at least one predefined scheduling policy. The predefined scheduling policy may comprise, for example, one or more of load balancing, server consolidation, maximizing the current utilizations, minimizing a response time of the parallel job and satisfying quality of service requirements. The load balancing can be achieved, for example, by assigning a task to a container having a highest potential free capacity. | 03-08-2012 |
20130024872 | Scheduling a Parallel Job in a System of Virtual Containers - Methods and apparatus are provided for scheduling parallel jobs in a system of virtual containers. At least one parallel job is assigned to a plurality of containers competing for a total capacity of a larger container, wherein the at least one parallel job comprises a plurality of tasks. The assignment method comprises determining a current utilization and a potential free capacity for each of the plurality of competing containers; and assigning the tasks to one of the plurality of containers based on the potential free capacities and at least one predefined scheduling policy. The predefined scheduling policy may comprise, for example, one or more of load balancing, server consolidation, maximizing the current utilizations, minimizing a response time of the parallel job and satisfying quality of service requirements. The load balancing can be achieved, for example, by assigning a task to a container having a highest potential free capacity. | 01-24-2013 |
20130235992 | PREFERENTIAL EXECUTION OF METHOD CALLS IN HYBRID SYSTEMS - Affinity-based preferential call technique, in one aspect, may improve performance of distributed applications in a hybrid system having heterogeneous platforms. A segment of code in a program being executed on a processor may be intercepted or trapped in runtime. A platform is selected in the hybrid system for executing said segment of code, the platform determined to run the segment of code with best efficiency among a plurality of platforms in the hybrid system. The segment of code is dynamically executed on the selected platform determined to run the segment of code with best efficiency. | 09-12-2013 |
20130239128 | PREFERENTIAL EXECUTION OF METHOD CALLS IN HYBRID SYSTEMS - Affinity-based preferential call technique, in one aspect, may improve performance of distributed applications in a hybrid system having heterogeneous platforms. A segment of code in a program being executed on a processor may be intercepted or trapped in runtime. A platform is selected in the hybrid system for executing said segment of code, the platform determined to run the segment of code with best efficiency among a plurality of platforms in the hybrid system. The segment of code is dynamically executed on the selected platform determined to run the segment of code with best efficiency. | 09-12-2013 |